DGX - CIK 0001022079
QUEST DIAGNOSTICS INC trades as DGX and has a market capitalization of $22.56 B, making it the #570 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $11.04B, up 11.8% from the prior year and net income of $992.00M. This page tracks QUEST DIAGNOSTICS INC through 2,372 SEC filings, with financial statements and metrics updated as new reports are filed.
Over the last 9 fiscal years QUEST DIAGNOSTICS INC's revenue grew from $7.21B to $11.04B, a compound annual growth rate of 4.8%. Net profit margin expanded from 8.9% to 9.0% over the same period - every figure below comes from the company's audited annual filings.
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
| Insider trade | 4 | 2026-05-21 |
**About Quest Diagnostics** Quest Diagnostics works across healthcare to create a healthier world, one life at a time. We connect people, from clinicians to consumers, with laboratory insights that illuminate a path to better health. With a focus on delivering smarter, simpler testing, we help reveal new avenues to identify and treat disease, empower healthy behaviors and improve healthcare management. Quest Diagnostics serves half the physicians and hospitals in the United States and one in three American adults each year, and our nearly 57,000 employees work together to deliver diagnostic insights that inspire actions to transform lives. www.QuestDiagnostics.com.
This press release shall not constitute an offer to sell or a solicitation of an offer to purchase any of these securities and shall not constitute an offer, solicitation or sale in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. This offering may be made only by means of a prospectus supplement and accompanying base prospectus, copies of which or information concerning this offering may be obtained by calling Goldman Sachs & Co. LLC, toll free at 1 (866) 471-2526, J.P. Morgan Securities LLC, collect at 1-212-834-4533 or Mizuho Securities USA LLC, toll free at 1-866-271-7403.
First quarter revenues of $2.90 billion, up 9.2% from 2025, with 9.0% organic revenue growth
The largest companies sharing QUEST DIAGNOSTICS INC's SEC industry classification (services-medical laboratories).
QUEST DIAGNOSTICS INC (DGX) has a market capitalization of $22.56 B as of 2026-06-10, ranking #570 among US-listed companies.
QUEST DIAGNOSTICS INC reported revenue of $11.04B for fiscal year 2025, an increase of 11.8% year over year.
Yes. QUEST DIAGNOSTICS INC reported net income of $992.00M in its latest fiscal year.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
**_Fourteen City of Hope sites across the U.S. participating in research using the Haystack MRD ctDNA Test in patients with breast, colorectal, ovarian, and prostate cancer_**
The conference call can be accessed by dialing 888-455-0391 within the U.S. and Canada, or 773-756-0467 internationally, using the passcode: "7895081." The earnings release and live webcast will be posted on www.QuestDiagnostics.com/investor. The company suggests participants dial in approximately 10 minutes before the call.